

February 1, 2010

**Kyowa Hakko Kirin and Hisamitsu entered into a Joint Distribution Agreement on Cancer Pain Drug (Development Code: KW-2246)**

Kyowa Hakko Kirin Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President: Yuzuru Matsuda; hereinafter “Kyowa Hakko Kirin”) and Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu, Saga; President: Hirotaka Nakanomi; hereinafter “Hisamitsu Pharmaceutical”) hereby announce today that they have entered into a joint distribution agreement in Japan for a cancer pain drug (development code: KW-2246), which is under development by Kyowa Hakko Kirin .

Under the terms of this agreement, KW-2246 will be jointly distributed by the two companies after Kyowa Hakko Kirin obtains its manufacturing and sales approval. After the product will be launched on the market, each company will carry out independent product distribution and information provision/gathering activities under a one-brand, two-channel setup.

KW-2246 is a drug for the treatment of acute pain (breakthrough pain) during the continuous management of cancer pain that Kyowa Hakko Kirin has in-licensed from Orexo AB (Head Office: Uppsala, Sweden; CEO: Torbjörn Bjerke). The Phase III clinical program has been already completed. Currently, the preparation for its new drug approval application has been undertaken.